Novo Nordisk India launches world’s first and only GLP-1 RA, oral semaglutide
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
Industry Report highlights the opportunities and need for multiple sectoral collaboration through 12 actionable recommendations under 6 thematic areas
He holds nine US patents and has published in multiple peer-reviewed journals and conferences
New capabilities on Philips Image Guided therapy mobile C-arm system – Zenition – and collaboration with Cydar offer the latest advances in endovascular treatment
The new plant at Slovenská ?up?a site in Slovakia is scheduled to come on stream in two years
In-house wet testing with live Omicron virus demonstrated that the Antigen test detects the Omicron variant with comparable sensitivity to other variants
Danny Bar-Zohar will become Global Head of R&D and Joern-Peter Halle will become Chief Strategy Officer
This advanced technology for Diabetic Foot Ulcer (DFU), management has a high scope of preventing amputations in diabetic patients. It has no definitive treatment in India. This technology will be available at affordable rates
The study will be published on the pre-print server, medRXiv, shortly
Subscribe To Our Newsletter & Stay Updated